DeepMed Research

SANOFI PASTEUR

🇫🇷France

Country: 🇫🇷France

Ownership: Subsidiary

Established: 1990-01-01

Employees: 10K

Market Cap: -

Website: http://www.sanofipasteur.com

Clinical Trials

Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adults in Thaïland

Phase 3

Completed

Conditions: Rabies (Healthy Volunteers)

Interventions: Biological: Purified inactivated rabies vaccine
Biological: Purified vero rabies vaccine - serum free
Biological: Human rabies immunoglobulins

First Posted Date: 2020-10-20

Last Posted Date: 2023-07-13

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 201

Registration Number: NCT04594551

Locations: 🇹🇭
Investigational site number 7640003, Bangkok, Thailand
🇹🇭
Investigational site number 7640001, Bangkok, Thailand
🇹🇭
Investigational site number 7640002, Bangkok, Thailand

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

Phase 4

Completed

Conditions: Healthy Volunteers
Influenza Immunization

Interventions: Biological: Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2020-2021 formulation
Biological: Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2020-2021 formulation

First Posted Date: 2020-09-16

Last Posted Date: 2023-10-03

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 90

Registration Number: NCT04551677

Locations: 🇺🇸
Investigational Site Number 8400002, Salt Lake City, Utah, United States
🇺🇸
Investigational Site Number 8400001, Bardstown, Kentucky, United States

Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age

Phase 3

Suspended

Conditions: Influenza

Interventions: Biological: Quadrivalent influenza vaccine, high-dose
Biological: Quadrivalent influenza vaccine, standard dose

First Posted Date: 2020-09-10

Last Posted Date: 2022-05-09

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 13320

Registration Number: NCT04544267

Locations: 🇺🇸
Investigational Site Number :8400033, Barnwell, South Carolina, United States
🇺🇸
Investigational Site Number :8400001, Atlanta, Georgia, United States
🇺🇸
Investigational Site Number :8400006, Salt Lake City, Utah, United States

and more 7 locations

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Taiwanese Adults 65 Years of Age and Older

Phase 3

Completed

Conditions: Influenza (Healthy Volunteers)

Interventions: Biological: High-Dose Quadrivalent Influenza Vaccine
Biological: Standard-Dose Quadrivalent Influenza Vaccine

First Posted Date: 2020-09-03

Last Posted Date: 2022-04-07

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 165

Registration Number: NCT04537234

Locations: 🇨🇳
Investigational Site Number 1580001, Taipei, Taiwan
🇨🇳
Investigational Site Number 1580002, Taipei, Taiwan
🇨🇳
Investigational Site Number 1580003, Taoyuan, Taiwan

and more 1 locations

Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older

Phase 1

Completed

Conditions: COVID-19 (Healthy Volunteers)

Interventions: Biological: CoV2 preS dTM-AS03 (low-dose)
Biological: CoV2 preS dTM-AS03 (high-dose)
Biological: Placebo (0.9% normal saline)
Biological: CoV2 preS dTM (high-dose) without adjuvant
Biological: CoV2 preS dTM-AF03 (high-dose)
Biological: CoV2 preS dTM-AF03 (low-dose)

First Posted Date: 2020-09-03

Last Posted Date: 2023-06-22

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 441

Registration Number: NCT04537208

Locations: 🇺🇸
Investigational Site Number 8400019, Melbourne, Florida, United States
🇺🇸
Investigational Site Number 8400004, Birmingham, Alabama, United States
🇺🇸
Investigational Site Number 8400011, Hollywood, Florida, United States

and more 8 locations

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older

Phase 3

Completed

Conditions: Healthy Volunteers
Influenza Immunization

Interventions: Biological: Local Standard-Dose Inactivated Quadrivalent Influenza Vaccine, 2020-2021 Strains (QIV-SD)
Biological: High-Dose Quadrivalent Influenza Vaccine, (Zonal Purified, Split Virus) 2020-2021 Strains (QIV-HD)

First Posted Date: 2020-08-05

Last Posted Date: 2023-10-03

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 2100

Registration Number: NCT04498832

Locations: 🇯🇵
Investigational Site Number 3920002, Suita-Shi, Japan
🇯🇵
Investigational Site Number 3920007, Toshima-Ku, Japan
🇯🇵
Investigational Site Number 3920005, Fukuoka-Shi, Japan

and more 7 locations

Study of an Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers

Phase 1

Completed

Conditions: Respiratory Syncytial Virus Infection

Interventions: Biological: RSV vaccine formulation 1
Biological: RSV vaccine formulation 2
Biological: Placebo

First Posted Date: 2020-07-29

Last Posted Date: 2024-06-13

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 259

Registration Number: NCT04491877

Locations: 🇺🇸
Pediatric Associates of Charlottesville North-Site Number:8400007, Charlottesville, Virginia, United States
🇺🇸
Matrix Clinical Research-Site Number:8400032, Los Angeles, California, United States
🇺🇸
The South Bend Clinic Center for Research-Site Number:8400024, South Bend, Indiana, United States

and more 26 locations

Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy Adolescents

Phase 3

Completed

Conditions: Meningococcal Immunisation
Healthy Volunteers

Interventions: Biological: Meningococcal group A, C, W-135, and Y conjugate vaccine
Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine (MenACYW Conjugate vaccine)
Biological: Human Papillomavirus 9-valent Vaccine (9vHPV)
Biological: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis Vaccine (Tdap-IPV)

First Posted Date: 2020-07-28

Last Posted Date: 2023-10-03

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 463

Registration Number: NCT04490018

Locations: 🇮🇹
Investigational Site Number :3800006, Catanzaro, Calabria, Italy
🇭🇺
Investigational Site Number :3480002, Miskolc, Hungary
🇭🇺
Investigational Site Number :3480006, Szombathely, Hungary

and more 20 locations

Dengvaxia US Pregnancy Registry

Recruiting

Conditions: Dengue Virus Infection

Interventions: Biological: Dengue Tetravalent Vaccine, Live

First Posted Date: 2020-07-24

Last Posted Date: 2024-12-02

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 500

Registration Number: NCT04486638

Locations: 🇵🇷
Investigational Site, Puerto Rico, Puerto Rico

Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adult and Pediatric Population in Thaïland

Phase 3

Completed

Conditions: Rabies (Healthy Volunteers)

Interventions: Biological: Purified vero rabies vaccine - serum free VRVg-2
Biological: Purified inactivated rabies vaccine
Biological: Equine rabies immunoglobulins (ERIG) (only Group 3 and Group 4)
Biological: Human rabies immunoglobulins (HRIG) (only Group 5 and Group 6)

First Posted Date: 2020-07-20

Last Posted Date: 2023-07-13

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 403

Registration Number: NCT04478084

Locations: 🇹🇭
Investigational Site Number :7640004, Bangkok, Thailand
🇹🇭
Investigational Site Number :7640002, Bangkok, Thailand
🇹🇭
Investigational Site Number :7640003, Khon Kaen, Thailand

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy